Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

462 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Discovery of novel serine palmitoyltransferase inhibitors as cancer therapeutic agents.
Kojima T, Asano Y, Kurasawa O, Hirata Y, Iwamura N, Wong TT, Saito B, Tanaka Y, Arai R, Yonemori K, Miyamoto Y, Sagiya Y, Yaguchi M, Shibata S, Mizutani A, Sano O, Adachi R, Satomi Y, Hirayama M, Aoyama K, Hiura Y, Kiba A, Kitamura S, Imamura S. Kojima T, et al. Among authors: mizutani a. Bioorg Med Chem. 2018 May 15;26(9):2452-2465. doi: 10.1016/j.bmc.2018.04.008. Epub 2018 Apr 4. Bioorg Med Chem. 2018. PMID: 29669694
A novel pyrrolo[3, 2-d]pyrimidine derivative, as a vascular endothelial growth factor receptor and platelet-derived growth factor receptor tyrosine kinase inhibitor, shows potent antitumor activity by suppression of tumor angiogenesis.
Awazu Y, Mizutani A, Nagase Y, Iwata H, Oguro Y, Miki H, Imamura S, Hori A. Awazu Y, et al. Among authors: mizutani a. Cancer Sci. 2012 May;103(5):939-44. doi: 10.1111/j.1349-7006.2012.02238.x. Epub 2012 Mar 15. Cancer Sci. 2012. PMID: 22320850 Free PMC article.
Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor tyrosine kinase.
Awazu Y, Mizutani A, Nagase Y, Tsuchiya S, Nakamura K, Kakoi Y, Kitahara O, Takeuchi T, Yamasaki S, Miyamoto N, Iwata H, Miki H, Imamura S, Hori A. Awazu Y, et al. Among authors: mizutani a. Cancer Sci. 2013 Apr;104(4):486-94. doi: 10.1111/cas.12101. Epub 2013 Feb 18. Cancer Sci. 2013. PMID: 23305239 Free PMC article.
Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication.
Ishikawa Y, Nakayama K, Morimoto M, Mizutani A, Nakayama A, Toyoshima K, Hayashi A, Takagi S, Dairiki R, Miyashita H, Matsumoto S, Gamo K, Nomura T, Nakamura K. Ishikawa Y, et al. Among authors: mizutani a. Oncogenesis. 2017 Sep 11;6(9):e377. doi: 10.1038/oncsis.2017.76. Oncogenesis. 2017. PMID: 28892104 Free PMC article.
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody.
Farrell PJ, Matuszkiewicz J, Balakrishna D, Pandya S, Hixon MS, Kamran R, Chu S, Lawson JD, Okada K, Hori A, Mizutani A, Iwata H, de Jong R, Hibner B, Vincent P. Farrell PJ, et al. Among authors: mizutani a. Mol Cancer Ther. 2017 Jul;16(7):1269-1278. doi: 10.1158/1535-7163.MCT-16-0771. Epub 2017 Mar 24. Mol Cancer Ther. 2017. PMID: 28341789
Correction: Synergistic anti-AML effects of the LSD1 inhibitor T-3775440 and the NEDD8-activating enzyme inhibitor pevonedistat via transdifferentiation and DNA rereplication.
Ishikawa Y, Nakayama K, Morimoto M, Mizutani A, Nakayama A, Toyoshima K, Hayashi A, Takagi S, Dairiki R, Miyashita H, Matsumoto S, Gamo K, Nomura T, Nakamura K. Ishikawa Y, et al. Among authors: mizutani a. Oncogenesis. 2019 Sep 11;8(9):51. doi: 10.1038/s41389-019-0160-0. Oncogenesis. 2019. PMID: 31511500 Free PMC article.
462 results